PE20000010A1 - DERIVADOS DE 2-OXO-IMIDAZOLIDINA, COMO ANTAGONISTAS DEL RECEPTOR DE INTEGRINA avß3 - Google Patents
DERIVADOS DE 2-OXO-IMIDAZOLIDINA, COMO ANTAGONISTAS DEL RECEPTOR DE INTEGRINA avß3Info
- Publication number
- PE20000010A1 PE20000010A1 PE1998001244A PE00124498A PE20000010A1 PE 20000010 A1 PE20000010 A1 PE 20000010A1 PE 1998001244 A PE1998001244 A PE 1998001244A PE 00124498 A PE00124498 A PE 00124498A PE 20000010 A1 PE20000010 A1 PE 20000010A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- aryl
- oxo
- compound
- integrin receptor
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 102000006495 integrins Human genes 0.000 title abstract 2
- 108010044426 integrins Proteins 0.000 title abstract 2
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical class O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 title 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 AMINOCARBONYL Chemical class 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical class [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Abstract
SE REFIERE A UN COMPUESTO I, LOS ATOMOS DEL DOBLE ENLACE SE SUSTITUYEN CON R11 Y R12; "X" ES -C(=NR1)-NR1R2, -NR1-C(=NR2)-NR1R2, ANILLO AROMATICO DE 5 o 6 MIEMBROS CON 0-4 N, O, S; ANILLO POLICICLICO DE 9-14 MIEMBROS CON 0-4 N, O, S; "Y" ES -(CH2)m-, -(CH2)m-O-(CH2)n-, -(CH2)mNR4-(CH2)n-, ENTRE OTROS; "Z" ES ANILLO MONO O POLICICLICO CON 0-4 N, O, S; CUALQUIER METILENO EN "Y" QUE NO TENGA R4 SE PUEDE SUSTITUIR CON 1-2 R3; R1 Y R2 SON H, HALOGENO, ALQUILO C1-C4, ENTRE OTROS; R3 ES H, ARILO, ALQUILO C1-C10, ENTRE OTROS, R4 ES H, ARILO, AMINOCARBONILO, ENTRE OTROS; R5 Y R6 SON H, ALQUILO C1-C6, ARILO, ENTRE OTROS; R7 Y R8 SON H, ALQUILO C1-C6, ARILO, ENTRE OTROS; R9 ES H, ALQUILO C1-C8; R10, R11, R12 Y R13 SON H, ALQUILO C1-C8, ARILO, ENTRE OTROS; m Y n SON 0-6; v ES 0-2. UN COMPUESTO PREFERIDO ES ACIDO 3(S)-(2,3-DIHIDRO-BENZOFURAN-6-ILO)-3-{2-OXO-3-[3-(5,6,7,8-TETRAHIDRO-[1,8]NAFTIRIDIN-2-ILO}-PROPIONICO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES ANTAGONISTA DEL RECEPTOR INTEGRINA Ovß3, Ovß5, Ovß6 Y ES UTIL PARA INHIBIR LA RESORCION DEL HUESO, TRATAMIENTO Y PREVENCION DE OSTEOPOROSIS, INHIBICION DE RESTENOSIS VASCULAR, RETINOPATIA DIABETICA, DEGENERACION MACULAR, ANGIOGENESIS, ATEROSCLEROSIS, INFLAMACION, CURAR HERIDAS, ENFERMEDADES VIRALES, CRECIMIENTO DE TUMORES, METASTASIS
Applications Claiming Priority (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6991097P | 1997-12-17 | 1997-12-17 | |
US7919798P | 1998-03-24 | 1998-03-24 | |
US7994498P | 1998-03-30 | 1998-03-30 | |
US8039798P | 1998-04-02 | 1998-04-02 | |
US8325198P | 1998-04-27 | 1998-04-27 | |
GBGB9810182.7A GB9810182D0 (en) | 1998-05-13 | 1998-05-13 | Vitronectin receptor antagonists |
GBGB9810882.2A GB9810882D0 (en) | 1998-05-20 | 1998-05-20 | Vitronectin receptor antagonists |
GBGB9810892.1A GB9810892D0 (en) | 1998-05-20 | 1998-05-20 | Vitronectin receptor antagonists |
GBGB9811283.2A GB9811283D0 (en) | 1998-05-26 | 1998-05-26 | Vironectin receptor antagonists |
GBGB9812686.5A GB9812686D0 (en) | 1998-06-12 | 1998-06-12 | Vitronectin receptor antagonists |
US9258898P | 1998-07-13 | 1998-07-13 | |
US9262498P | 1998-07-13 | 1998-07-13 | |
US9994898P | 1998-09-11 | 1998-09-11 | |
GBGB9822331.6A GB9822331D0 (en) | 1998-10-13 | 1998-10-13 | Vitronectin receptor antagonists |
GBGB9822701.0A GB9822701D0 (en) | 1998-10-16 | 1998-10-16 | Intergrin receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20000010A1 true PE20000010A1 (es) | 2000-01-29 |
Family
ID=27585232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1998001244A PE20000010A1 (es) | 1997-12-17 | 1998-12-17 | DERIVADOS DE 2-OXO-IMIDAZOLIDINA, COMO ANTAGONISTAS DEL RECEPTOR DE INTEGRINA avß3 |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP1040111B1 (es) |
JP (2) | JP3589633B2 (es) |
KR (2) | KR20010024748A (es) |
AT (1) | ATE298338T1 (es) |
AU (1) | AU741769B2 (es) |
BG (1) | BG104601A (es) |
CA (1) | CA2315189C (es) |
DK (1) | DK1040111T3 (es) |
EA (1) | EA003095B1 (es) |
EE (1) | EE200000360A (es) |
ES (1) | ES2243016T3 (es) |
HU (1) | HUP0100178A3 (es) |
IL (1) | IL136314A0 (es) |
IS (1) | IS5513A (es) |
NO (1) | NO317975B1 (es) |
NZ (1) | NZ504896A (es) |
PE (1) | PE20000010A1 (es) |
PL (1) | PL341095A1 (es) |
PT (1) | PT1040111E (es) |
SI (1) | SI1040111T1 (es) |
SK (1) | SK9162000A3 (es) |
TR (1) | TR200001752T2 (es) |
WO (1) | WO1999031099A1 (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999030709A1 (en) * | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
JP2002522540A (ja) * | 1998-08-13 | 2002-07-23 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
CN1398189A (zh) * | 1998-12-23 | 2003-02-19 | G.D.西尔公司 | 用于***形成的放疗与cox-2抑制剂的联合治疗 |
KR20010108499A (ko) | 1999-04-13 | 2001-12-07 | 스타르크, 카르크 | 인테그린 수용체 리간드 |
US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
BR0011108A (pt) | 1999-06-02 | 2002-03-19 | Merck & Co Inc | Composto, composição farmacêutica, e, processos de eliciar um efeito antagonizante do receptor da integrina, de tratamento ou prevenção da osteoporose, de tratamento ou prevenção de uma condição mediada por antagonismo de um receptor de integrina, de inibição da reabsorção óssea em um mamìfero em necessidade do mesmo, e de tratamento do desenvolvimento tumoral |
DE19936780A1 (de) * | 1999-08-09 | 2001-02-15 | Basf Ag | Neue Antagonisten von Integrinrezeptoren |
US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
JP2003510360A (ja) * | 1999-10-04 | 2003-03-18 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
US6407241B1 (en) | 1999-11-08 | 2002-06-18 | Merck & Co., Inc. | Process and intermediates for the preparation of imidazolidinone αv integrin antagonists |
WO2001034602A2 (en) * | 1999-11-08 | 2001-05-17 | Merck & Co., Inc. | Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists |
GB2356630A (en) | 1999-11-10 | 2001-05-30 | Merck & Co Inc | Intermediates used in the preparation of tetrahydronaphthyridine |
AU768875B2 (en) | 1999-11-23 | 2004-01-08 | Merck Sharp & Dohme Corp. | Process and intermediates to a tetrahydro-(1,8)-naphthyridine |
US6849639B2 (en) | 1999-12-14 | 2005-02-01 | Amgen Inc. | Integrin inhibitors and their methods of use |
US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
CA2397194C (en) * | 2000-01-20 | 2011-05-17 | Mark E. Duggan | Alpha v integrin receptor antagonists |
ATE375330T1 (de) | 2000-04-17 | 2007-10-15 | Ucb Pharma Sa | Enamin-derivate als zell-adhäsionsmoleküle |
US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
EP1301488A1 (en) | 2000-07-07 | 2003-04-16 | Celltech R&D Limited | Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists |
WO2002010136A1 (en) | 2000-08-02 | 2002-02-07 | Celltech R & D Limited | 3-substituted isoquinolin-1-yl derivatives |
AU9088401A (en) * | 2000-09-13 | 2002-03-26 | Merck & Co Inc | Alpha v integrin receptor antagonists |
CA2421652A1 (en) | 2000-09-14 | 2002-03-21 | Merck And Co., Inc. | Alpha v integrin receptor antagonists |
JP2004517853A (ja) * | 2001-01-03 | 2004-06-17 | メルク エンド カムパニー インコーポレーテッド | 歯周病の治療方法及び治療用組成物 |
ES2200617B1 (es) | 2001-01-19 | 2005-05-01 | Almirall Prodesfarma, S.A. | Derivados de urea como antagonistas de integrinas alfa 4. |
ATE510557T1 (de) | 2001-04-24 | 2011-06-15 | Merck Patent Gmbh | Kombinationstherapie mit antiangiogenen mitteln und tnfalpha |
US6855724B2 (en) | 2002-04-08 | 2005-02-15 | Agouron Pharmaceuticals, Inc. | Tropane derivatives useful in therapy |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
US20070299114A1 (en) * | 2004-10-05 | 2007-12-27 | Shionogi & Co., Ltd. | Biaryl Derivatives |
WO2007084670A2 (en) | 2006-01-18 | 2007-07-26 | Merck Patent Gmbh | Specific therapy using integrin ligands for treating cancer |
DE102006024024A1 (de) | 2006-05-23 | 2007-11-29 | Bayer Healthcare Aktiengesellschaft | Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung |
ES2399159T3 (es) | 2007-01-18 | 2013-03-26 | Merck Patent Gmbh | Terapia y medicamento específicos usando ligandos de integrinas para el tratamiento del cáncer |
CN104225613A (zh) | 2008-03-14 | 2014-12-24 | Visen医药公司 | 整联蛋白靶向试剂及使用其的体内和体外成像方法 |
DE102008060967A1 (de) | 2008-12-06 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylsulfonyltriazolone und ihre Verwendung |
DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
CA2763275A1 (en) | 2009-05-25 | 2010-12-02 | Merck Patent Gmbh | Continuous administration of integrin ligands for treating cancer |
BR112012021498B8 (pt) | 2010-02-27 | 2020-04-14 | Bayer Ip Gmbh | ariltriazolonas ligadas a bisaril e seu uso |
DE102010040187A1 (de) | 2010-09-02 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung |
DE102010040924A1 (de) | 2010-09-16 | 2012-03-22 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung |
US8901144B2 (en) | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
US9518053B2 (en) | 2013-02-07 | 2016-12-13 | Scifluor Life Sciences, Inc. | Fluorinated integrin antagonists |
PL3050878T3 (pl) | 2013-09-24 | 2022-01-24 | Fujifilm Corporation | Zawierający atom azotu związek lub jego sól, lub ich kompleks z metalem |
MX2016015467A (es) | 2014-05-30 | 2017-03-23 | Pfizer | Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos. |
CU24462B1 (es) | 2014-11-03 | 2020-01-03 | Bayer Pharma AG | Derivados de feniltriazol sustituido con hidroxialquilo |
KR102647026B1 (ko) * | 2015-02-19 | 2024-03-12 | 사이플루어 라이프 사이언시즈, 인크 | 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도 |
WO2017189828A1 (en) * | 2016-04-27 | 2017-11-02 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
MA47692A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
EP3589627A4 (en) | 2017-02-28 | 2020-08-05 | Morphic Therapeutic, Inc. | INHIBITORS OF (ALPHA-V) (BETA-6) -INTEGRIN |
UY38353A (es) | 2018-08-29 | 2020-03-31 | Morphic Therapeutic Inc | Inhibición de integrina alfavbeta6 |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1598073A (en) * | 1976-12-18 | 1981-09-16 | Beecham Group Ltd | 8,10,12-triazaprostaglandins |
DE2965098D1 (en) * | 1978-06-15 | 1983-05-05 | Beecham Group Plc | 1.2.4-triazolidine-3.5-dione derivatives, process for their preparation and pharmaceutical compositions containing them |
DE3042466A1 (de) * | 1980-11-11 | 1982-06-16 | A. Nattermann & Cie GmbH, 5000 Köln | N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
WO1991018888A1 (en) * | 1990-05-25 | 1991-12-12 | G.D. Searle & Co. | N-substituted-1,2,4-triazolone compounds for treatment of cardiovascular disorders |
US5416099A (en) * | 1991-10-29 | 1995-05-16 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
CA2129897C (en) * | 1992-02-11 | 2006-01-10 | James David Winkler | Coa-it and paf inhibitors |
JPH10501222A (ja) * | 1994-05-27 | 1998-02-03 | メルク エンド カンパニー インコーポレーテッド | 破骨細胞仲介骨吸収を抑制するための化合物 |
-
1998
- 1998-12-14 PT PT98963915T patent/PT1040111E/pt unknown
- 1998-12-14 SK SK916-2000A patent/SK9162000A3/sk unknown
- 1998-12-14 EE EEP200000360A patent/EE200000360A/xx unknown
- 1998-12-14 TR TR2000/01752T patent/TR200001752T2/xx unknown
- 1998-12-14 SI SI9830777T patent/SI1040111T1/xx unknown
- 1998-12-14 JP JP2000539023A patent/JP3589633B2/ja not_active Expired - Lifetime
- 1998-12-14 DK DK98963915T patent/DK1040111T3/da active
- 1998-12-14 IL IL13631498A patent/IL136314A0/xx unknown
- 1998-12-14 HU HU0100178A patent/HUP0100178A3/hu unknown
- 1998-12-14 EA EA200000653A patent/EA003095B1/ru not_active IP Right Cessation
- 1998-12-14 ES ES98963915T patent/ES2243016T3/es not_active Expired - Lifetime
- 1998-12-14 EP EP98963915A patent/EP1040111B1/en not_active Expired - Lifetime
- 1998-12-14 AT AT98963915T patent/ATE298338T1/de active
- 1998-12-14 WO PCT/US1998/026568 patent/WO1999031099A1/en active IP Right Grant
- 1998-12-14 PL PL98341095A patent/PL341095A1/xx not_active Application Discontinuation
- 1998-12-14 KR KR1020007006653A patent/KR20010024748A/ko active IP Right Grant
- 1998-12-14 CA CA002315189A patent/CA2315189C/en not_active Expired - Lifetime
- 1998-12-14 KR KR10-2003-7005778A patent/KR20030048081A/ko not_active Application Discontinuation
- 1998-12-14 AU AU19144/99A patent/AU741769B2/en not_active Expired
- 1998-12-14 NZ NZ504896A patent/NZ504896A/xx unknown
- 1998-12-17 PE PE1998001244A patent/PE20000010A1/es not_active Application Discontinuation
-
2000
- 2000-05-26 IS IS5513A patent/IS5513A/is unknown
- 2000-06-16 NO NO20003113A patent/NO317975B1/no not_active IP Right Cessation
- 2000-07-13 BG BG104601A patent/BG104601A/bg unknown
-
2004
- 2004-06-24 JP JP2004185935A patent/JP2004300158A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EA003095B1 (ru) | 2002-12-26 |
AU741769B2 (en) | 2001-12-06 |
CA2315189A1 (en) | 1999-06-24 |
JP2002508374A (ja) | 2002-03-19 |
DK1040111T3 (da) | 2005-10-10 |
PL341095A1 (en) | 2001-03-26 |
SI1040111T1 (en) | 2005-10-31 |
ES2243016T3 (es) | 2005-11-16 |
BG104601A (bg) | 2001-01-31 |
AU1914499A (en) | 1999-07-05 |
NO20003113D0 (no) | 2000-06-16 |
ATE298338T1 (de) | 2005-07-15 |
WO1999031099A1 (en) | 1999-06-24 |
JP3589633B2 (ja) | 2004-11-17 |
NO20003113L (no) | 2000-08-16 |
KR20010024748A (ko) | 2001-03-26 |
PT1040111E (pt) | 2005-10-31 |
NZ504896A (en) | 2002-10-25 |
EP1040111B1 (en) | 2005-06-22 |
IL136314A0 (en) | 2001-05-20 |
TR200001752T2 (tr) | 2000-12-21 |
KR20030048081A (ko) | 2003-06-18 |
EP1040111A1 (en) | 2000-10-04 |
EE200000360A (et) | 2001-12-17 |
SK9162000A3 (en) | 2001-03-12 |
HUP0100178A3 (en) | 2002-12-28 |
CA2315189C (en) | 2005-04-19 |
JP2004300158A (ja) | 2004-10-28 |
HUP0100178A2 (hu) | 2001-11-28 |
EA200000653A1 (ru) | 2000-12-25 |
IS5513A (is) | 2000-05-26 |
NO317975B1 (no) | 2005-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20000010A1 (es) | DERIVADOS DE 2-OXO-IMIDAZOLIDINA, COMO ANTAGONISTAS DEL RECEPTOR DE INTEGRINA avß3 | |
TWI265931B (en) | Composition and method for inhibiting platelet aggregation | |
PT1074542E (pt) | Compostos de indole contendo sulfonamida | |
NZ504893A (en) | 5, 6, 7, 8-Tetrahydro-[1,8]-naphthyridin-2-yl derivatives useful as integrin receptor antagonists | |
BR0112475A (pt) | N-óxidos como pró-drogas antagonistas de receptor de nk1 de derivados 4-fenil-piridina | |
DE60035496D1 (de) | Indolinderivate als progesteron antagonisten | |
GT199800180A (es) | Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos. | |
EA200401056A1 (ru) | Комбинация, содержащая производные тропана, полезные в терапии | |
BRPI0412314A (pt) | derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina | |
ES2164939T3 (es) | Derivados de 1-(1,2-piperidinil disustituido)-4-piperidina sustituida como antagonistas de receptores de taquicinina. | |
PA8547901A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
HN1999000080A (es) | Derivados de isotiazol utiles como agentes anticancerosos. | |
HUP0001162A2 (hu) | Pirrolo-benzodiazepin-, -kinoxalin-, -pirazin-származékok és az ezeket tartalmazó gyógyszerkészítmények | |
BRPI0518068A (pt) | composto ou um éster ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor seletivo de aurora a, agente anti-tumor, e, preparação combinada | |
AR034270A1 (es) | 1-aril- o 1-alquilsulfonil-heterociclilbenzazoles como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, una composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento | |
ECSP034796A (es) | DERIVADOS DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-ONA ANTAGONISTAS I MGLUR2 | |
AR002268A1 (es) | Antagonistas de vasopresina de benzacepina triciclicos, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso dedichos compuestos para preparar composiciones farmaceuticas. | |
ME00149B (me) | Postupci i farmaceutski sastavi za pouzdano postizanje prihvatljivih nivoa seruma testosterona | |
IL104090A (en) | Phosphonosuccinic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing these compounds | |
PA8589601A1 (es) | Derivados de indazol como antagonistas del crf | |
AR015222A1 (es) | Benzotiadiazoles, proceso para su preparacion, composicion farmaceutica que los contiene y su uso para la manufactura de un medicamento | |
BG94282A (bg) | 2,9-дизаместени-4н-пиридо/1,2,-а/пиримидин-4-они | |
MX9806171A (es) | Derivados 2,3-benzodiazepina y sus usos como inhibidores del receptor-ampa. | |
MY129176A (en) | Tetrahydro gamma-carbolines | |
BR9806263A (pt) | Derivados de 1,2,3,4-tetrahidro-benzofuro[3,2-c]piridina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |